Every 10-Q that XBiotech Inc (XBIT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XBIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIT filings page.
XBiotech Inc. reported a net loss of $6.7 million for the quarter and $12.2 million for the six months ended June 30, 2026, similar to the $12.6 million loss in the prior-year period. There was no revenue, and the company does not expect to generate revenue in 2026 as it remains a clinical-stage biopharmaceutical developer.
Operating expenses declined materially: six‑month research and development costs fell to $10.5 million from $17.0 million, and general and administrative expenses decreased to $1.9 million from $2.9 million, partly reflecting the absence of a large 2025 bonus and option grant to the former CEO. Foreign exchange swung to a $2.5 million loss from a $3.4 million gain, limiting improvement in bottom-line results.
XBiotech ended the quarter with $109.5 million in cash and cash equivalents and $128.5 million of shareholders’ equity, with minimal liabilities and no outstanding debt. Management states this cash is expected to fund operations for at least 12 months and to complete key clinical inflection points, including Phase II trials for IL‑1a‑targeting antibodies in oncology and axial spondyloarthritis. A workforce reduction was implemented after quarter-end, with related costs not expected to be material. Disclosure controls and internal control over financial reporting were assessed as effective.
XBiotech Inc. reported a net loss of $5.5 million for the three months ended March 31, 2026, an improvement from a $10.9 million loss a year earlier. Loss per share narrowed to $0.18 from $0.36 on a stable share count of 30,487,731.
Total operating expenses fell sharply as research and development dropped to $5.2 million from $11.6 million and general and administrative costs declined to $1.1 million from $1.9 million, largely reflecting lower bonuses and stock-based compensation linked to the former CEO.
The company ended the quarter with cash and cash equivalents of $115.5 million and total assets of $139.8 million, against shareholders’ equity of $135.0 million. Management states this cash should fund operations for at least 12 months, but it does not expect any revenue in 2026 and anticipates continued operating losses as it advances its True Human™ antibody pipeline.
XBiotech Inc. reported Q3 2025 results, posting a net loss of $6.0 million as operating expenses fell with no active clinical trials. Cash and cash equivalents were $147.4 million at September 30, 2025, supporting ongoing R&D and facility plans.
Research and development expense was $5.1 million in Q3 (down from $7.1 million), mainly from lower clinical and manufacturing activity. General and administrative expense was $1.0 million. Other income reflected $1.4 million of interest income and a $1.2 million foreign exchange loss. For the nine months, net loss was $18.6 million.
The company repaid in full a $10 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. On October 2, 2025, XBiotech entered a new executive employment agreement with its CEO, providing a $1,250,000 base salary, eligibility for a $4,530,442 base bonus, and severance equal to three years of base salary and base bonus upon certain separations. Shares outstanding were 30,487,731 as of November 12, 2025.
XBiotech Inc. reported narrower losses in the quarter ended June 30, 2025 with a three-month net loss of $1.8 million and a six-month net loss of $12.6 million, down from $13.0 million and $23.0 million a year earlier. Revenue remained nil and operating expenses fell as clinical trial activity decreased and certain executive compensation timing shifted; research and development totaled $5.3 million for the quarter and $17.0 million year-to-date. The company held $152.9 million in cash and cash equivalents at June 30, 2025, down from $172.7 million at December 31, 2024, and used $12.7 million of cash in operations during the six months ended June 30, 2025.
The company repaid and terminated a $10.0 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. Total assets were $178.7 million and shareholders' equity was $173.1 million as of June 30, 2025. XBiotech states its cash is sufficient to achieve several major inflection points and to fund operations for at least 12 months from the report date.